Released on = November 9, 2006, 7:07 am

Press Release Author = Gentris Corporation

Industry = Pharmaceuticals

Press Release Summary = Dr. Andrea Gaedigk of Children's Mercy Hospital & Clinics
joins advisory board of leading scientists

Press Release Body = Research Triangle Park, North Carolina - November 9, 2006 -
Gentris Corporation (Gentris), a leading global provider of applied clinical
pharmacogenomic services and diagnostic product solutions, today announced the
appointment of Andrea Gaedigk, M.S., Ph.D. to the company's Scientific Advisory
Board.

Dr. Gaedigk's work encompasses basic and translational research at Children's Mercy
Hospital & Clinics, where she directs the Pharmacogenetics Core Laboratory within
the Division of Pediatric Clinical Pharmacology and Medical Toxicology. Dr. Gaedigk
is considered a leading specialist on the pharmacogenetics of drug metabolizing
enzymes, in particular, the cytochrome P450s. She has published over 60
peer-reviewed papers and presented her work in over 100 abstracts at national and
international scientific conferences. She serves as a co-investigator on numerous
NIH-funded projects.

"Every member of this world-class Scientific Advisory Board provides specific
expertise and knowledge of a discipline that is critical to rapid development,
regulatory approval and commercialization of Gentris products or services," said
Gentris CEO, Michael P. Murphy. "The members of our Scientific Advisory Board also
share our vision of a future where drug delivery is safer and more personalized for
each patient."

Welcoming Dr. Gaedigk are fellow Gentris Scientific Advisory Board members: William
E. Evans, Pharm.D., Director, St. Jude's Children's Hospital; Janice Kurth, M.D.,
Ph.D., Vice President of Life Sciences, Visualize Inc.; and Paul A. Andrews, Ph.D.,
R.A.C., Head of Toxicology Department, ImClone.

About Gentris Corporation
Gentris Corporation is a leading global provider of applied clinical pharmacogenomic
services and diagnostic product solutions. As pioneers in the field of
pharmacogenomics, Gentris helps pharmaceutical companies and clinical research
organizations effectively integrate pharmacogenomics into their drug development
programs to deliver safer, more effective compounds to the market sooner. Gentris is
developing validated reference controls and diagnostic test kits that will bring the
promise of personalized medicine to physicians and patients, which will enhance
patient management, improve patients\' response to therapy and revolutionize medicine
through pharmacogenomics. For additional information, please visit
http://www.gentris.com.



Web Site = http://www.gentris.com

Contact Details = Jonathan Jordan
919 Marketing/919.557.7890
press@gentris.com